The Kinghorn Cancer Centre eNews Issue 9 – December 2011

[button url=”” style=”grey” size=”small”] Download PDF [/button]

The Kinghorn Cancer Centre construction update

Delta Goodrem, along with the nation’s media, recently conducted a hard-hat tour of The Kinghorn Cancer Centre (TKCC), of which she is a patron, to review construction developments and to leave her hand prints in concrete.

During the tour, Delta stated to the assembled media, “I wanted to be the patron of this centre and was honoured when asked. It’s something so phenomenal and evolutionary, and the fact we will have such an amazing and incredible facility here in Sydney is so important to me.

“To have such a personal connection, and the fact that the actual centre is about personalised medicine, is truly incredible.”

Construction has progressed well with ‘topping out’ now complete for the bulk of the building. The second tower crane has been removed from site, while structure works focus on the atrium completion.

Services are being installed throughout, including key equipment such as the chiller plant and substation. Partition works have progressed to level 8 with the building very much taking its final shape.

Breakthroughs are complete to the Garvan boardroom, as well as the new link at Garvan’s de novo cafe. Work has now commenced in the car park connection to the Lowy Packer Building.

Cancer research news from Garvan
Australian philanthropist Mr Daniel Petre recently donated $2m to appoint a Chair of Prostate Cancer Research at the University of Sydney, who will work closely with researchers at the Garvan Institute of Medical Research. It is the first such Chair in Australia.

Professor Rob Sutherland AO FAA, Director of the Garvan Institute’s Cancer Research Program and inaugural Director of TKCC said, “The funds provided by the Petre family will help us seek and engage the best possible prostate cancer expert.”

The Petre Foundation also supports a Chair of Breast Cancer Research at the Garvan Institute.

Cancer services/care news from St Vincent’s
By Professor Allan Spigelman, Director, St Vincent’s Cancer and Immunology Program

The last few months have seen TKCC reach its full dimensions, so that the clinical teams that are now touring the site in increasing numbers have been able to observe at first-hand how the vision is being turned into a physical reality.

Encouraging reports from other centres of excellence world-wide provide support for the emerging frontier science of using a person’s cancer’s genetic profile to direct truly personalised therapy, in tumours ranging from bowel cancer to melanoma, with the blood malignancy multiple myeloma also being the subject of an early report outlining candidate high risk genes. Truly exciting times, as we move closer to occupying TKCC, a centre that has the delivery of such advances as a core outcome. This key objective is also akin to that outlined in the Blueprint for Transforming Clinical and Translational Cancer Research released by the American Society of Clinical Oncology in November 2011. On that score, the delivery of the next tranche of funds from the Nelune Foundation, as part of its generous donation to fund the Nelune Centre where such treatments will be given, is gratefully noted.